1. Yousef GM, Diamandis EP. The new human tissue kallikrein gene family: structure, function, and association to disease. Endocr Rev. 2001; 22:184–204.
![crossref](/image/icon/bnr_ref_cross.gif)
2. Borgoño CA, Diamandis EP. The emerging roles of human tissue kallikreins in cancer. Nat Rev Cancer. 2004; 4:876–890.
![crossref](/image/icon/bnr_ref_cross.gif)
3. Jin Y, Qu S, Tesikova M, Wang L, Kristian A, Mælandsmo GM, et al. Molecular circuit involving KLK4 integrates androgen and mTOR signaling in prostate cancer. Proc Natl Acad Sci U S A. 2013; 110:E2572–E2581.
![crossref](/image/icon/bnr_ref_cross.gif)
4. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987; 317:909–916.
![crossref](/image/icon/bnr_ref_cross.gif)
5. Nagahara H, Mimori K, Utsunomiya T, Barnard GF, Ohira M, Hirakawa K, et al. Clinicopathologic and biological significance of kallikrein 6 overexpression in human gastric cancer. Clin Cancer Res. 2005; 11:6800–6806.
![crossref](/image/icon/bnr_ref_cross.gif)
6. Schuster R, Max N, Mann B, Heufelder K, Thilo F, Gröne J, et al. Quantitative real-time RT-PCR for detection of disseminated tumor cells in peripheral blood of patients with colorectal cancer using different mRNA markers. Int J Cancer. 2004; 108:219–227.
![crossref](/image/icon/bnr_ref_cross.gif)
7. Nathalie HV, Chris P, Serge G, Catherine C, Benjamin B, Claire B, et al. High kallikrein-related peptidase 6 in non-small cell lung cancer cells: an indicator of tumour proliferation and poor prognosis. J Cell Mol Med. 2009; 13:9B. 4014–4022.
![crossref](/image/icon/bnr_ref_cross.gif)
8. Shan SJ, Scorilas A, Katsaros D, Diamandis EP. Transcriptional upregulation of human tissue kallikrein 6 in ovarian cancer: clinical and mechanistic aspects. Br J Cancer. 2007; 96:362–372.
![crossref](/image/icon/bnr_ref_cross.gif)
9. Vakrakou A, Devetzi M, Papachristopoulou G, Malachias A, Scorilas A, Xynopoulos D, et al. Kallikrein-related peptidase 6 (KLK6) expression in the progression of colon adenoma to carcinoma. Biol Chem. 2014; 395:1105–1117.
10. Klucky B, Mueller R, Vogt I, Teurich S, Hartenstein B, Breuhahn K, et al. Kallikrein 6 induces E-cadherin shedding and promotes cell proliferation, migration, and invasion. Cancer Res. 2007; 67:8198–8206.
![crossref](/image/icon/bnr_ref_cross.gif)
11. Kim JT, Song EY, Chung KS, Kang MA, Kim JW, Kim SJ, et al. Up-regulation and clinical significance of serine protease kallikrein 6 in colon cancer. Cancer. 2011; 117:2608–2619.
![crossref](/image/icon/bnr_ref_cross.gif)
12. Sawada K, Mitra AK, Radjabi AR, Bhaskar V, Kistner EO, Tretiakova M, et al. Loss of E-cadherin promotes ovarian cancer metastasis via alpha 5-integrin, which is a therapeutic target. Cancer Res. 2008; 68:2329–2339.
13. Kim TW, Lee SJ, Kim JT, Kim SJ, Min JK, Bae KH, et al. Kallikrein-related peptidase 6 induces chemotherapeutic resistance by attenuating auranofin-induced cell death through activation of autophagy in gastric cancer. Oncotarget. 2016; 7:85332–85348.
![crossref](/image/icon/bnr_ref_cross.gif)
14. Masoumi Moghaddam S, Amini A, Morris DL, Pourgholami MH. Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer. Cancer Metastasis Rev. 2012; 31:143–162.
![crossref](/image/icon/bnr_ref_cross.gif)
15. Deryugina EI, Quigley JP. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev. 2006; 25:9–34.
![crossref](/image/icon/bnr_ref_cross.gif)
16. Carcas LP. Gastric cancer review. J Carcinog. 2014; 13:14.
![crossref](/image/icon/bnr_ref_cross.gif)
17. Van Cutsem E, Sagaert X, Topal B, Haustermans K, Prenen H. Gastric cancer. Lancet. 2016; 388:2654–2664.
![crossref](/image/icon/bnr_ref_cross.gif)
18. Lenga Ma Bonda W, Iochmann S, Magnen M, Courty Y, Reverdiau P. Kallikrein-related peptidases in lung diseases. Biol Chem. 2018; 399:959–971.
![crossref](/image/icon/bnr_ref_cross.gif)
19. Kim JJ, Kim JT, Yoon HR, Kang MA, Kim JH, Lee YH, et al. Upregulation and secretion of kallikrein-related peptidase 6 (KLK6) in gastric cancer. Tumour Biol. 2012; 33:731–738.
20. Oikonomopoulou K, Diamandis EP, Hollenberg MD. Kallikrein-related peptidases: proteolysis and signaling in cancer, the new frontier. Biol Chem. 2010; 391:299–310.
![crossref](/image/icon/bnr_ref_cross.gif)
21. Sananes A, Cohen I, Shahar A, Hockla A, De Vita E, Miller AK, et al. A potent, proteolysis-resistant inhibitor of kallikrein-related peptidase 6 (KLK6) for cancer therapy, developed by combinatorial engineering. J Biol Chem. 2018; 293:12663–12680.
22. Sidiropoulos KG, Ding Q, Pampalakis G, White NM, Boulos P, Sotiropoulou G, et al. KLK6-regulated miRNA networks activate oncogenic pathways in breast cancer subtypes. Mol Oncol. 2016; 10:993–1007.
![crossref](/image/icon/bnr_ref_cross.gif)